消化器病市場の市場規模、シェア、成長分析、タイプ別、流通チャネル別、用途別、投与経路別、地域別 - 産業予測、2025～2032年

消化器病の世界市場規模は2023年に374億米ドルと評価され、予測期間（2025-2032年）のCAGRは5.9%で、2024年の626億5,000万米ドルから2032年には626億5,000万米ドルに成長する見通しです。

消化器病市場は、食生活の乱れや高齢者人口の増加を主因とする消化器疾患の有病率の増加により、著しい成長を遂げています。消化器疾患の急増は入院や外科手術の増加につながり、主要企業は生物製剤やバイオシミラー医薬品の研究開発強化に取り組んでいます。さらに、2021年5月時点で6,443件の臨床試験が進行中という臨床試験の拡大は、細胞療法や低分子化合物を含む革新的治療のための強力なパイプラインを示しています。ヘルスケアを取り巻く環境が進化する中、こうした開発は効果的な治療法の新たな機会をもたらし、今後数年間の消化器病市場の成長をさらに後押しします。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

消化器病市場規模：タイプ別

• 市場概要
• ブランド
• ジェネリック

消化器病市場規模：流通チャネル別

• 市場概要
• 小売薬局
• 病院薬局
• オンライン薬局

消化器病市場規模：用途別

• 市場概要
• クローン病
• 潰瘍性大腸炎
• GERD
• IBS
• その他

消化器病市場規模：投与経路別

• 市場概要
• 注射可能
• 経口およびその他

消化器病市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• AbbVie Inc.（US）
• Takeda Pharmaceutical Company Limited（Japan）
• AstraZeneca plc（UK）
• Bayer AG（Germany）
• Pfizer Inc.（US）
• Johnson & Johnson（US）
• Novartis AG（Switzerland）
• Merck & Co., Inc.（US）
• Sanofi S.A.（France）
• GlaxoSmithKline plc（UK）
• Boehringer Ingelheim International GmbH（Germany）
• Teva Pharmaceutical Industries Limited（Israel）
• Boston Scientific Corporation（US）
• Medtronic plc（Ireland）
• Olympus Corporation（Japan）
• Fujifilm Corporation（Japan）
• Stryker Corporation（US）
• Nestle Health Science（Switzerland）
• Danone S.A.（France）

結論と推奨事項

Global Gastroenterology Market size was valued at USD 37.4 billion in 2023 and is poised to grow from USD 62.65 billion in 2024 to USD 62.65 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The gastroenterology market is witnessing significant growth, driven by the increasing prevalence of gastrointestinal diseases, largely attributable to poor dietary habits and a growing elderly population. The surge in gastrointestinal disorders has led to a rise in hospitalizations and surgical interventions, prompting biopharmaceutical companies to intensify their R&D efforts in biologics and biosimilars. Additionally, the expansion of clinical trials, with 6,443 ongoing studies as of May 2021, indicates a robust pipeline for innovative treatments, including cellular therapies and small compounds. As the healthcare landscape evolves, these developments present new opportunities for effective therapies, further propelling the growth of the gastroenterology market in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroenterology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastroenterology Market Segmental Analysis

Global Gastroenterology Market is segmented by type, distribution channel, application, route of administration and region. Based on type, the market is segmented into branded and generics. Based on distribution channel, the market is segmented into retail pharmacies, hospital pharmacies and online pharmacies. Based on application, the market is segmented into crohn's disease, ulcerative colitis, Gerd, IBS and others. Based on route of administration, the market is segmented into injectable and oral & others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastroenterology Market

The global gastroenterology market is being significantly influenced by the rising incidence of gastrointestinal diseases, such as gallstones, ulcerative colitis, hemorrhoids, and irritable bowel syndrome (IBS). Factors contributing to the increasing prevalence of both chronic and acute gastrointestinal conditions include unhealthy dietary choices, sedentary lifestyles, heightened stress levels, food sensitivities, and bacterial or viral infections. Consequently, there is a growing demand for various medications, including antacids, proton pump inhibitors, histamine H2-receptor antagonists, and antibiotics, to effectively manage these disorders and prevent related health complications. This surge in healthcare needs is propelling the expansion of the global market for gastroenterology therapeutics.

Restraints in the Global Gastroenterology Market

The global gastroenterology market is expected to encounter considerable challenges during the forecast period, primarily due to the escalating costs associated with treatments. Various gastrointestinal disorders, including chronic conditions like Crohn's disease and ulcerative colitis, require ongoing management to prevent recurrence and potential complications such as cancer. The comprehensive treatment expenses encompass medication costs, consultations, and hospital admissions, which significantly contribute to the overall financial burden. For instance, biologic therapies such as infliximab and vedolizumab can range from $6,000 to $8,700 per prescription, while monthly costs for some treatments can vary between $2,500 and $5,500. These increasing out-of-pocket expenses for treatments and procedures are likely to hinder the market's growth.

Market Trends of the Global Gastroenterology Market

The global gastroenterology market is poised for significant growth, fueled by the rising prevalence of gastrointestinal disorders like ulcerative colitis and Crohn's disease. Pharmaceutical and biotechnology companies are increasingly investing in research and development to innovate cutting-edge therapies, expanding their product pipelines to meet this growing demand. This trend is marked by a strong focus on developing revolutionary treatments that promise enhanced efficacy for patients. As both regional and global players ramp up their efforts in drug development, the global therapeutics market for gastrointestinal diseases is expected to thrive, presenting substantial opportunities for stakeholders over the forecast period.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Gastroenterology Market Size by Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generics

Global Gastroenterology Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Global Gastroenterology Market Size by Application & CAGR (2025-2032)

• Market Overview
• Crohn's Disease
• Ulcerative Colitis
• Gerd
• IBS
• Others

Global Gastroenterology Market Size by Route Of Administration & CAGR (2025-2032)

• Market Overview
• Injectable
• Oral & Others

Global Gastroenterology Market Size & CAGR (2025-2032)

• North America (Type, Distribution Channel, Application, Route Of Administration)
  • US
  • Canada
• Europe (Type, Distribution Channel, Application, Route Of Administration)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Distribution Channel, Application, Route Of Administration)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Distribution Channel, Application, Route Of Administration)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Distribution Channel, Application, Route Of Administration)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Limited (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olympus Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle Health Science (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danone S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations